The Effect of Antipsychotics on Cognition in Schizophrenia-A Current Narrative Review
- PMID: 38672011
- PMCID: PMC11047912
- DOI: 10.3390/brainsci14040359
The Effect of Antipsychotics on Cognition in Schizophrenia-A Current Narrative Review
Abstract
The majority of schizophrenia-affected individuals display deficiencies in multiple cognitive domains such as attention, working memory, long-term memory, and learning, deficiencies that are stable throughout the disease. The purpose of this narrative review was to examine the effect of antipsychotics on several cognitive domains affected by schizophrenia. Methods: We searched MEDLINE, Elsevier, Scopus, and DOAJ databases for randomized controlled trials and other studies investigating the effects of typical and atypical antipsychotics on cognition in patients with schizophrenia in studies conducted in the last decade. Results: The majority of studies included in this review showed that antipsychotics (especially SGAs) have positive effects on both cognition and general psychopathology of schizophrenia. We mention that treatment with antipsychotic substances represents an ongoing effort of the researchers, who are constantly searching for the best approach to meet the mental health needs of schizophrenia patients. Conclusions: Even with those positive results, it should be noted that more studies are needed in order to fully observe the various effects of certain antipsychotic substances on cognition.
Keywords: antipsychotics; cognition; schizophrenia.
Conflict of interest statement
The authors declare no conflict of interest.
Figures
Similar articles
-
Cognitive and psychomotor effects of risperidone in schizophrenia and schizoaffective disorder.Clin Ther. 2008 Sep;30(9):1565-89. doi: 10.1016/j.clinthera.2008.09.014. Clin Ther. 2008. PMID: 18840365 Review.
-
Anti-Dementia Drugs for Psychopathology and Cognitive Impairment in Schizophrenia: A Systematic Review and Meta-Analysis.Int J Neuropsychopharmacol. 2018 Aug 1;21(8):748-757. doi: 10.1093/ijnp/pyy045. Int J Neuropsychopharmacol. 2018. PMID: 29762677 Free PMC article.
-
Long-acting atypical antipsychotics in schizophrenia: A systematic review and meta-analyses of effects on functional outcome.Aust N Z J Psychiatry. 2019 Jun;53(6):509-527. doi: 10.1177/0004867419837358. Epub 2019 Apr 8. Aust N Z J Psychiatry. 2019. PMID: 30957510
-
Disparate effects of first and second generation antipsychotics on cognition in schizophrenia - Findings from the randomized NeSSy trial.Eur Neuropsychopharmacol. 2019 Jun;29(6):720-739. doi: 10.1016/j.euroneuro.2019.03.014. Epub 2019 Apr 10. Eur Neuropsychopharmacol. 2019. PMID: 30981585 Clinical Trial.
-
Comparing the effect of the subcategories of atypical antipsychotic medications on cognition in schizophrenia using a meta-analytic approach.J Clin Exp Neuropsychol. 2019 Feb;41(1):26-42. doi: 10.1080/13803395.2018.1488952. Epub 2018 Jul 20. J Clin Exp Neuropsychol. 2019. PMID: 30025491
Cited by
-
D3 Receptor-Targeted Cariprazine: Insights from Lab to Bedside.Int J Mol Sci. 2024 May 23;25(11):5682. doi: 10.3390/ijms25115682. Int J Mol Sci. 2024. PMID: 38891871 Free PMC article. Review.
References
-
- WHO . International Statistical Classification of Diseases and Related Health Problems ICD-10: Instruction Manual. Volume 2. World Health Organization—WHO; Geneva, Switzerland: 2016. [(accessed on 5 November 2023)]. p. 252. Available online: https://icd.who.int/browse10/Content/statichtml/ICD10Volume2_en_2016.pdf.
-
- Barrera A., Curwell-Parry O., Raphael M.-C. Hebephrenia is dead, long live hebephrenia, or why Hecker and Chaslin were on to something. BJPsych Adv. 2019;25:373–376. doi: 10.1192/bja.2019.24. - DOI
-
- American Psychiatric Association . Diagnostic and Statistical Manual of Mental Disorders. American Psychiatric Association; Arlington, VA, USA: 2013. - DOI
Publication types
LinkOut - more resources
Full Text Sources